SHH · 600085.SS
Beijing Tongrentang Co., Ltd
CN¥25.07+CN¥0.64 (+2.62%)
Beijing Tongrentang Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 30.11% below the high.
Loading market information…
SHZ · 300181.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Zhejiang Jolly Pharmaceutical Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 35.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Zhejiang Jolly Pharmaceutical Co.,LTD’s forward annual dividend is CN¥1.40 per share, paid quarterly. The forward yield is 11.67% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Zhejiang Jolly Pharmaceutical Co.,LTD’s next earnings report is currently expected on Apr 22, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zhejiang Jolly Pharmaceutical Co.,LTD’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥824.00M+0.24% vs estimate |
| Q4 2024 | Mar 10, 2025 | CN¥0.12 | CN¥533.00M |
|---|
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥25.07+CN¥0.64 (+2.62%)
Beijing Tongrentang Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 30.11% below the high.
CN¥18.75-CN¥0.04 (-0.21%)
Tibet Cheezheng Tibetan Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.84% below the high.
CN¥4.21+CN¥0.04 (+0.96%)
Zhejiang CONBA Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.57% below the high.
CN¥8.14+CN¥0.07 (+0.87%)
Jiuzhitang Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 24.91% below the high.
CN¥4.45-CN¥0.01 (-0.22%)
Guizhou Bailing Group Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.8% below the high.
CN¥4.70+CN¥0.01 (+0.21%)
Shanghai Kaibao Pharmaceutical CO.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 30.58% below the high.
CN¥9.57-CN¥0.02 (-0.21%)
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD’s quoted price sits in the lower half of its reported 52-week range, 54.34% below the high.
CN¥7.74-CN¥0.29 (-3.61%)
Guhan Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.39% below the high.
